Table 1.
Baseline demographic and clinical characteristics of patients who underwent Helicobacter pylori eradication
| Parameters | Patients (n = 85) |
| Age, mean (SD), yr | 56.1 (12.3) |
| Gender, n (%) | |
| Female | 53 (62.4) |
| BMI, mean (SD), kg/m2 | 25.1 (2.2) |
| Alcohol users (12-24 g/dL /die), n (%) | 27 (31.8) |
| Previous smokers, n (%) | 12 (14.1) |
| Drug users, n (%) | 23 (27.1) |
| Family history of gastric cancer, n (%) | 4 (4.7) |
| Family history of other cancer, n (%) | 9 (10.6) |
| Autoimmune comorbidity | |
| Autoimmune atrophic gastritis | 12 (14.1) |
| Autoimmune thyroiditis | 6 (7.1) |
| Type-1/2 diabetes mellitus | 3 (3.5) |
| Skin psoriasis | 1 (1.2) |
| Rheumatoid arthritis | 1 (1.2) |
| Sjögren syndrome | 1 (1.2) |
| A. thyroiditis + vitiligo | 1 (1.2) |
| A. thyroiditis + Crohn’s disease | 1 (1.2) |
| A. thyroiditis + Sjögren syndrome | 1 (1.2) |
| APCA and/or AIF antibody positivity | 12 (14.1) |
| Endoscopy indication, n (%) | |
| Gastroesophageal reflux | 17 (20) |
| Recurrent abdominal pain | 12 (14.1) |
| Dyspepsia | 41 (48.2) |
| Unexplained anemia | 15 (17.7) |
| H. pylori eradication scheme, n (%) | |
| Quadruple1 | 53 (62.4) |
| Modified triple2 | 28 (32.9) |
| Triple3 | 3 (3.6) |
| Sequential4 | 1 (1.2) |
| H. pylori eradication cycles, n (%) | |
| One-cycle | 71 (83.5) |
| Two-cycles | 14 (16.5) |
Data are expressed as number of patients and percentage (in parenthesis).
1
Bismuth + Metronidazole + Tetracycline + Proton pump inhibitor.
2
Amoxicillin + Levofloxacin + Proton pump inhibitor.
3
Amoxicillin + Clarithromycin + Proton pump inhibitor.
4
Amoxicillin + Clarithromycin + Proton pump inhibitor Amoxicillin (5 d), then Clarithromycin + Metronidazole (5 d) + Proton pump inhibitor. BMI: Body mass index; SD: Standard deviation; APCA: Anti-parietal cell antibody; AIF: Anti-intrinsic factor; H. pylori: Helicobacter pylori; PPI: Proton pump inhibitor.